Comparative Pharmacology
Head-to-head clinical analysis: OXCARBAZEPINE EXTENDED RELEASE TABLETS versus ZONISADE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXCARBAZEPINE EXTENDED RELEASE TABLETS versus ZONISADE.
OXCARBAZEPINE EXTENDED RELEASE TABLETS vs ZONISADE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by blocking voltage-sensitive sodium channels, inhibiting repetitive firing of action potentials, and reducing the propagation of synaptic impulses. Also modulates calcium channels and enhances potassium conductance.
Zonisamide is a sulfonamide anticonvulsant. Its precise mechanism of action is unknown, but it is believed to inhibit voltage-sensitive sodium channels and reduce T-type calcium currents, thereby stabilizing neuronal membranes and suppressing neuronal hypersynchronization. It may also modulate GABA and glutamate neurotransmission.
Initial: 300 mg orally twice daily. Increase by up to 600 mg/day at weekly intervals. Target maintenance: 1200-2400 mg/day in two divided doses. Extended-release tablets are dosed once daily: initial 600 mg, titrate weekly by 600 mg to maintenance 1200-2400 mg once daily.
100-200 mg orally every 8 hours; maximum 600 mg/day.
None Documented
None Documented
Oxcarbazepine: ~2 hours (not clinically relevant due to rapid conversion to MHD). MHD: ~9 hours (steady-state achieved in 2-3 days).
Terminal elimination half-life: 63-69 hours in adults; allows once-daily dosing; steady-state achieved in 14-21 days
Renal: ~70% (mainly as glucuronide conjugates of MHD and oxcarbazepine, with <1% unchanged oxcarbazepine and ~27% unchanged MHD). Fecal: <1%.
Renal: approximately 62% (35% unchanged, 27% as glucuronide conjugate); fecal: 3%; biliary: negligible
Category C
Category C
Anticonvulsant
Anticonvulsant